The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.

×

Search

×
26 Mar 2020

The AMA is aware of reports regarding hydroxychloroquine and its inappropriate use as a therapeutic for COVID-19, and has responded quickly to this issue by working with the Department of Health and the TGA. 

This medication is important for many patients, particularly those with auto-immune disorders, and it is essential that these patients continue to have a supply.  

As of 24 March 2020, there are new restrictions for prescribing hydroxychloroquine. Initial treatment of hydroxychloroquine must be authorised by a medical practitioner under the following specialties: 

  • Dermatology
  • Intensive care medicine
  • Paediatrics and child health 
  • Physician
  • Emergency medicine

Published: 26 Mar 2020